Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04018001 · ClinicalTrials.gov registry record
Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,057
- Enrollment target
NCT04018001: Completed study, sponsored by Pfizer.
NCT04018001 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,057 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04018001 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,057 participants
- Enrollment target
Study Summary
The purpose of this study is to compare adherence, persistence, and effectiveness among patients initiating tofacitinib Modified Release (MR) with tofacitinib Immediate Release (IR).
Primary Outcome
Effectiveness criteria: 1) High adherence with proportion of days covered greater than or equal to \[\>=\] 0.8; 2) No increase in index medication dose; 3) No use of an advanced therapy other than index therapy 4) No addition/claims of conventional synthetic disease-modifying antirheumatic drug; 5) If no oral glucocorticoid prescriptions in the 6 months prior to index date, then no more than 30 total days supply of oral glucocorticoids between 3-12 months post index or if at least 1 claim for or
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,057 participants |
| Start Date | 2019-04-12 |
| Est. Completion | 2019-04-25 |
What the finished NCT04018001 record still lists
NCT04018001 is an observational study that tracks outcomes without assigning an intervention. Its 1,057 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04018001 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04018001 about?
NCT04018001 is a clinical study titled "Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)". The purpose of this study is to compare adherence, persistence, and effectiveness among patients initiating tofacitinib Modified Release (MR) with tofacitinib Immediate Release (IR).
What is the current status of trial NCT04018001?
This trial is currently completed. The enrollment target is 1,057 participants. The study started on 2019-04-12. Estimated completion is 2019-04-25.
Who is sponsoring clinical trial NCT04018001?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07018869 · 1,057 participants · Phase 3
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- NCT03588286 · 1,058 participants · NA
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
- NCT03242642 · 1,056 participants · NA
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
- NCT04372108 · 1,056 participants
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI